Beranda › Kanker Paru › Rhode Island
Uji klinis Kanker Paru di Rhode Island
6 studi untuk Kanker Paru mencari peserta di lokasi di Rhode Island.
Kota di Rhode Island
Teks studi resmi (Bahasa Inggris)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Rhode Island Hospital, Providence
- Roger Williams Medical Center, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kent Hospital, Warwick
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Lifespan Cancer Institute, Providence
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Smilow Cancer Hospital Care Center - Westerly, Westerly
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
- Rhode Island and the Miriam Hospitals (Brown University Health), Providence
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Okt 2025 · NCT06974604Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.